1. Endocytosis and degradation of monoclonal antibodies targeting human B-cell malignancies;Press;Cancer Res,1989
2. Retention of B-cell-specific monoclonal antibodies by human lymphoma cells;Press;Blood,1994
3. Use of rituximab, the new FDA-approved antibody;Leget;Curr Opin Oncol,1998
4. Clinical applications of anti-CD20 antibodies;Gopal;J Lab Clin Med,1999
5. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study;Coiffier;Blood,1998